Clinical Trial Update: Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors

View source ↗

Summary

This clinical trial update describes immune-related toxicity and symptom burden in chronic melanoma survivors receiving adjuvant immune checkpoint inhibitors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8 | Status: ACTIVE_NOT_RECRUITING